CompletedPhase 2NCT02583893
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Studying Therapy related acute myeloid leukemia and myelodysplastic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Principal Investigator
- Margaret Kasner, MDThomas Jefferson University
- Intervention
- Sirolimus(drug)
- Enrollment
- 39 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2023
Study locations (1)
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02583893 on ClinicalTrials.gov